公开(公告)号：US20230210982A1

公开(公告)日：2023-07-06

申请号：US18061045

申请日：2022-12-02

Applicant: AIVITA BIOMEDICAL, INC

Inventor： Gabriel NISTOR ,  Hans KIERSTEAD ,  Robert O. DILLMAN

IPC: A61K39/215 ,  C12N5/0784

CPC classification number: A61K39/215 ,  C12N5/0639 ,  C12N2501/2304 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/24 ,  A61K2039/5154

Abstract: Disclosed herein is a kit to produce a personalized vaccine based on autologous dendritic cells. The kit contains all the materials, reagents and information necessary to produce a dose of live dendritic cell vaccine against a pathogen organism, part of a pathogen organism, a toxin, a venom, a structure obtained by recombinant method or chemical synthesis.

公开(公告)号：US20240299282A1

公开(公告)日：2024-09-12

申请号：US18139825

申请日：2023-04-26

Applicant: AiVita Biomedical, Inc.

Inventor： Gabriel NISTOR

IPC: A61K8/73 ,  A61K8/64 ,  A61K9/00 ,  A61K9/08 ,  A61K38/17 ,  A61K38/18 ,  A61K47/26 ,  A61K47/40 ,  A61K47/54 ,  A61K47/61 ,  A61K47/69 ,  A61Q7/00 ,  C07K14/47 ,  C12N5/00 ,  C12N5/0735 ,  C12N5/074

CPC classification number: A61K8/738 ,  A61K8/64 ,  A61K9/0014 ,  A61K9/08 ,  A61K38/1709 ,  A61K38/18 ,  A61K47/26 ,  A61K47/40 ,  A61K47/543 ,  A61K47/61 ,  A61K47/6951 ,  A61Q7/00 ,  C07K14/4705 ,  C12N5/0018 ,  C12N5/0606 ,  C12N5/0607 ,  A61K2800/56 ,  C12N2500/34

Abstract: Disclosed herein are compositions comprising complexes of cyclodextrins and lipid-modified stem cell proteins. Also disclosed are topical compositions the complexes. Methods of using the compositions for the therapeutic purposes are also disclosed as well as methods of producing the compositions.

公开(公告)号：US20220347277A1

公开(公告)日：2022-11-03

申请号：US17698608

申请日：2022-03-18

Applicant: AIVITA BIOMEDICAL, INC.

Inventor： Gabriel NISTOR ,  Andrew N. CORNFORTH ,  Robert O. DILLMAN

IPC: A61K39/00 ,  A61K35/15 ,  C12N5/0784 ,  C12N5/09

Abstract: The present specification provides methods for augmenting the antigenic content, especially of tumor-associated antigens (TAA), and immunogenicity of cancer cells; methods for enhancing cross-presentation in dendritic cells, compositions comprising such manipulated cells derived from single cancer patients; and methods of using those compositions as a personal immunotherapeutic product to treat the donor patient's cancer.